Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya.
Romy E van Weelderen, Festus Njuguna, Kim Klein...
https://pubmed.ncbi.nlm.nih.gov/34811958/Actively Recruiting
Led by Baylor College of Medicine · Updated on 2026-07-15
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
This research aims to evaluate the implementation of pediatric acute myeloid leukemia AML treatment guidelines adapted for resource-limited settings like Malawi. The study focuses on children under 18 years diagnosed with de novo AML at Kamuzu Central Hospital, where survival rates are notably low. It assesses a clinical practice guideline CPG based on recommendations by the International Society of Paediatric Oncology SIOP, designed to balance effective treatment with manageable side effects in this setting. The study observes patients treated according to the 2023 KCH AML therapy CPG, which is the current standard of care at the hospital. The guideline involves intensity-adapted chemotherapy cycles including induction and consolidation phases, with inpatient care during chemotherapy cycles until recovery milestones. Patients then have a brief home period before the next cycle. Data collection includes routine clinical care measurements like bone marrow evaluations, blood tests, imaging, and patient questionnaires, with no extra procedures required for study participation. Participants will be followed during therapy and after treatment completion, with monthly telephone check-ins for six months and in-person visits up to two years and beyond. The study measures implementation success by combining feasibility and effectiveness, including treatment completion rates and remission outcomes. Additional outcomes include survival, adverse events, hematologic recovery, cytogenetics, and quality of life assessments. This is the first prospective pediatric AML study in sub-Saharan Africa aimed at improving care in low-resource environments.
CONDITIONS
Leukemia Adapted Protocol
C
Casey McAtee, M.D., M.P.H.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Baylor College of Medicine
Lead Sponsor
American Society of Hematology
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants receive chemotherapy according to the intensity-adapted pediatric AML guidelines. They are admitted to the hospital for each chemotherapy cycle until blood counts improve, followed by a short home period before the next cycle.
Multiple inpatient stays and outpatient visits during chemotherapy cycles
Duration - Up to 2 years or more
After treatment, participants have monthly telephone follow-ups for six months and in-person visits at regular intervals up to two years and beyond to monitor health and quality of life.
Monthly phone calls for 6 months, plus visits at 3, 6, 9, 12, 18, and 24 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Romy E van Weelderen, Festus Njuguna, Kim Klein...
https://pubmed.ncbi.nlm.nih.gov/34811958/Eunice Chakumatha, Janna Weijers, Kondwani Banda...
https://pubmed.ncbi.nlm.nih.gov/32391955/David M Holmes, Apatsa Matatiyo, Atupele Mpasa...
https://pubmed.ncbi.nlm.nih.gov/36798020/Marina Elena Cazzaniga, Nicoletta Cordani, Serena Capici...
https://pubmed.ncbi.nlm.nih.gov/34066606/Yixin Hu, Aili Chen, Xinchang Zheng...
https://pubmed.ncbi.nlm.nih.gov/34691895/Scott C Howard, Alan Davidson, Sandra Luna-Fineman...
https://pubmed.ncbi.nlm.nih.gov/29297619/Stephen P Hunger, Charles G Mullighan
https://pubmed.ncbi.nlm.nih.gov/26465987/Kim Klein, Eric G Haarman, Valerie de Haas...
https://pubmed.ncbi.nlm.nih.gov/27093190/Deepak Bansal, Alan Davidson, Eddy Supriyadi...
https://pubmed.ncbi.nlm.nih.gov/31774234/Ichiro Tsukimoto, Akio Tawa, Keizo Horibe...
https://pubmed.ncbi.nlm.nih.gov/19620491/Baylor College of Medicine
Lead Sponsor
American Society of Hematology
Collaborating Sponsor